# Efficacy and Safety of DLBS1425 as Neoadjuvant in Stage II or III Breast Cancer Patients

> **NCT01433562** · PHASE2,PHASE3 · COMPLETED · sponsor: **Dexa Medica Group** · enrollment: 40 (actual)

## Conditions studied

- Breast Cancer

## Interventions

- **DRUG:** DLBS1425
- **DRUG:** Placebo DLBS1425

## Key facts

- **NCT ID:** NCT01433562
- **Lead sponsor:** Dexa Medica Group
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2,PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2011-08
- **Primary completion:** 2012-11
- **Final completion:** 2012-11
- **Target enrollment:** 40 (ACTUAL)
- **Last updated:** 2013-05-13


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01433562

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01433562, "Efficacy and Safety of DLBS1425 as Neoadjuvant in Stage II or III Breast Cancer Patients". Retrieved via AI Analytics 2026-05-28 from https://api.ai-analytics.org/clinical/NCT01433562. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*